Summary
Puma Biotechnology, Inc. (Puma) is a biopharmaceutical company that develops and markets therapeutics for the treatment of cancer. The company concentrates on in-licensing drug candidates which undergoes initial clinical testing and develops those drug candidates for commercial use. It has developed PB272-oral neratinib, a potent irreversible tyrosine kinase inhibitor, for the treatment of HER2-positive breast cancer and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation. The company serves the patients throughout the US. Puma is headquartered in Los Angeles, California, the US.
Puma Biotechnology, Inc. (PBYI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Puma Biotechnology, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Puma Biotechnology, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Puma Biotechnology, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Puma Biotechnology, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Puma Biotechnology, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Puma Biotechnology, Inc., Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Puma Biotech Secures Additional US$5 Million In Financing 10
Licensing Agreements 12
Puma Biotech Amends Licensing Agreement with Pfizer for Neratinib 12
Pfizer Enters Into Licensing Agreement With Puma Biotech For Neratinib 14
Puma Enters into Licensing Agreement with Pfizer for Neratinib 16
Equity Offering 17
Puma Biotech Raises USD218.5 Million in Public Offering of Shares 17
Puma Biotech Completes Public Offering Of Shares For US$138 Million 19
Puma Biotech Completes Public Offering Of Common Stock For US$138 Million 21
Acquisition 23
Innovative Acquisitions Acquires Puma Biotech In Reverse Acquisition 23
Puma Biotechnology, Inc. - Key Competitors 24
Key Employees 25
Locations And Subsidiaries 26
Head Office 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27
List of Tables
Puma Biotechnology, Inc., Pharmaceuticals & Healthcare, Key Facts, 2015 1
Puma Biotechnology, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Puma Biotechnology, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Puma Biotechnology, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Puma Biotechnology, Inc., Deals By Therapy Area, 2010 to YTD 2016 8
Puma Biotechnology, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Puma Biotech Secures Additional US$5 Million In Financing 10
Puma Biotech Amends Licensing Agreement with Pfizer for Neratinib 12
Pfizer Enters Into Licensing Agreement With Puma Biotech For Neratinib 14
Puma Enters into Licensing Agreement with Pfizer for Neratinib 16
Puma Biotech Raises USD218.5 Million in Public Offering of Shares 17
Puma Biotech Completes Public Offering Of Shares For US$138 Million 19
Puma Biotech Completes Public Offering Of Common Stock For US$138 Million 21
Innovative Acquisitions Acquires Puma Biotech In Reverse Acquisition 23
Puma Biotechnology, Inc., Key Competitors 24
Puma Biotechnology, Inc., Key Employees 25
List of Figures
Puma Biotechnology, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Puma Biotechnology, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Puma Biotechnology, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Puma Biotechnology, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Puma Biotechnology, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Puma Biotechnology, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Puma Biotechnology, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Puma Biotechnology, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8